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ABSTRACT
Whole genome sequencing analysis of 100 Neisseria meningitidis serogroup A isolates has revealed
that the csaABCD-ctrABCD-ctrEF capsule polysaccharide synthesis locus represents a spontaneous
point mutation hotspot. Structural and functional properties of the capsule of 11 carriage and two
disease isolates with non-synonymous point mutations or stop codons in capsule synthesis genes
were analyzed for their capsular polysaccharide expression, recognition by antibodies and sensi-
tivity to bactericidal killing. Eight of eleven carriage isolates presenting capsule locus mutations
expressed no or reduced amounts of capsule. One isolate with a stop codon in the
O-acetyltransferase gene expressed non-O-acetylated polysaccharide, and was not recognized
by anti-capsule antibodies. Capsule and O-acetylation deficient mutants were resistant to com-
plement deposition and killing mediated by anti-capsular antibodies, but not by anti-lipopoly-
saccharide antibodies. Two capsule polymerase mutants, one carriage and one case isolate,
showed capsule over-expression and increased resistance against bactericidal activity of both
capsule- and lipopolysaccharide-specific antibodies. Meningococci have developed multiple stra-
tegies for changing capsule expression and structure, which is relevant both for colonization and
virulence. Here we show that point mutations in the capsule synthesis genes substantially
contribute to the repertoire of genetic mechanisms in natural populations leading to variability
in capsule expression.
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Introduction
Neisseria meningitidis is an obligate human pathogen
that colonizes the human nasopharyngeal mucosa and
occasionally invades the bloodstream, causing severe
invasive disease such as septicemia or meningitis [1].
Countries of the African ‘meningitis belt’ have for over
100 years experienced large meningococcal meningitis
epidemics [2–4]. Multilocus sequence typing (MLST) of
carriage and disease isolates has shown that between the
late 1980s and 2010, epidemic waves of colonization and
disease were mainly associated with hypervirulent ser-
ogroup A clones with the sequence types (ST) 5, 7, and
2859 [5–8]. The ST-5 clone spread in the meningitis belt
after an epidemic in Mecca in 1987. The ST-7 and the
ST-2859 clone were found in Africa for the first time in
1995 and 2003, respectively [9–11]. Comparative whole
genome sequencing analyzes showed that the ST-2859
lineage evaded herd immunity elicited by their ST-7
ancestors primarily through rapid homologous replace-
ment of a set of genomic loci affecting non-capsular cell
surface components [12].
The closely related A clones, namely, ST-5, 7 and
2859 followed each other in different geographical set-
tings, each colonizing the local population for a few
years before being replaced [13–15]. Due to horizontal
gene transfer and point mutations, clonal meningococ-
cal populations are, even in the course of an epidemic,
not absolutely identical. Analysis of ST-7 and ST-2859
serogroup A isolates isolated between 2001 and 2009 in
the framework of longitudinal meningococcal coloniza-
tion and disease surveys in Ghana and Burkina Faso
identified the pilT-pilU locus, which is implicated in the
regulation of type IV pilus expression, and the
csaABCD-ctrABCD-ctrEF capsule synthesis locus (cps)
as point mutation hot spot regions [12].
The capsular genes are clustered within the cps chro-
mosomal locus and divided into six regions, designated
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A-D, D’ and E. Genes in region A (csaABCD) encode
for polysaccharide biosynthesis and polymerization
enzymes [16]. Proteins encoded by genes in region B
(ctrE and ctrF) and C (ctrABCD) are involved in trans-
location of the polysaccharide from the cytoplasm to
the cell surface. Region D encoded proteins are
required for lipopolysaccharide (LPS) synthesis. Genes
in region D’ encode methyltransferases and region D
genes which are duplicated and truncated (galE). The
function of region E is unknown. The serogroup A
polysaccharide consists of repeating units of (α1-6)-
linked N-acetyl-mannosamine-1-phosphate synthesized
by enzymes encoded by genes designated mynA-D or
csaA-D [16–18]. The repeating units are O-acetylated
mainly at position C3 and sometimes at position
C4 [17].
Meningococci have developed a range of genetic
mechanisms to modify expression and structure of
their capsule [19]. These include phase variation by
slipped-strand miss-pairing, transcriptional regulation,
post-transcriptional regulation via RNA thermosensors,
insertion element (IS) associated on-off switching and
‘capsule switching’ by horizontal gene transfer. Among
the 100 clonally related serogroup A isolates analyzed
by comparative whole genome sequencing, Lamelas
et al. [12] identified 13 isolates with non-synonymous
single nucleotide polymorphisms (SNPs) or stop
codons in the capsule synthesis locus. In contrast,
none of the 100 sequenced isolates carried a synon-
ymous point mutation in this locus, speaking for selec-
tion of variants. Here we describe the phenotypic,
structural and functional effects caused by the non-
synonymous point mutations and stop codons in the
cps locus.
Materials and methods
Neisseria meningitidis isolates
The serogroup A N. meningitidis isolates investigated in
this study (Table 1) have been collected in the frame-
work of longitudinal meningococcal colonization and
disease studies in the Kassena-Nankana District (KND)
and the neighboring Bolgatanga district (BA) hospital of
Ghana and in the Nouna Health District (NHD) of
Burkina Faso. Case isolates were obtained from the
cerebrospinal fluid of meningitis patients and carriage
isolates from throat swabs. For the longitudinal menin-
gococcal colonization studies with a sample size of about
300 participants, residential compounds in the KND and
the NHD were selected and throat swabs were taken
twice annually from all consenting members of the
selected compounds present at the time of the visit
[15,20,21]. Isolation and characterization of bacterial
isolates [15,20,21], and the comparative whole genome
analysis of these isolates [12] have been described pre-
viously. Ethical clearance was obtained from the relevant
institutional review boards and the Ministries of Health.
Informed consent for use of the samples was obtained
from all study participants.
Monoclonal antibodies and antisera
Polyclonal antisera reactive with the serogroup A cap-
sule were obtained from mice immunized with the
Menveo A, C, W, Y capsule polysaccharide conjugate
vaccine (anti-ACWY capsule antiserum). The N.
meningitidis LPS specific monoclonal antibody (mAb)
EI9.2 of the IgG subclass IgG2a was produced in-house
(anti-LPS mAb), and the serogroup A capsule specific
mAb 95/674 (anti-A capsule mAb) [22] was obtained
from the National Institute for Biological Standards and
Control (Potters Bar, Hertfordshire, UK).
Analysis of capsule expression by flow cytometry
Isolates were cultured at 37°C, 5% CO2 to an OD600 of
0.7 in Mueller-Hinton broth (MH; Becton Dickinson
AG; Allschwil, Switzerland), washed, inactivated with
4% (v/v) formalin and re-suspended in Dulbecco’s
phosphate buffered saline containing 0.5% (w/v) bovine
serum albumin (DPBS-BSA, Sigma-Aldrich, St. Louis,
MO, USA). Cell suspensions were incubated with
10 μg/mL anti-A capsule mAb 95/674 or with a 1:50
dilution of the polyclonal anti-ACWY capsule anti-
serum for 1 hour at room temperature. Alexa Fluor
488-conjugated goat anti-mouse IgG (heavy and light
chain) specific antibodies (Invitrogen, Carlsbad, CA,
USA) were used as secondary antibody at a 1:200 dilu-
tion. Cells re-suspended in FACS flow buffer (Becton
Dickinson AG) were analyzed using a FACS Calibur
(Becton Dickinson AG) FL2-H channel and the soft-
ware CellQuest Pro version 5.2.1 (Becton Dickinson
AG). For all experiments, the cells were gated at
30,000 events. Results were reproduced in two indepen-
dent experiments.
Flow cytometric analysis of C3b and C4b deposition
For C3b and C4b deposition experiments, 100 μL of
formalin inactivated bacterial cells in DPBS-BSA were
incubated with polyclonal anti-ACWY capsule anti-
serum at a 1:50 dilution or with 4 μg/mL anti-LPS
mAb for 1 hour at room temperature (C3b) or at 4°C
(C4b). Subsequently, 2% human serum from a healthy
individual with no detectable bactericidal activity against
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the test isolates was added as complement source. The
serum was depleted of IgG by passing it over a HiTrap
rProtein G FF column (GE Healthcare Life Sciences,
Little Chalfont, UK) and filter sterilized. Removal of
IgG was verified by enzyme-linked immunosorbent
assay (ELISA). After 15 minutes of incubation at 4°C,
100 μL of FITC conjugated rabbit polyclonal anti-C3c
antibodies (ab4212, diluted 1:2,000; Abcam, Cambridge,
UK) or anti-C4c + C4b antibodies (ab4216, diluted
1:3,000; Abcam) were added for 1 hour at 4°C. Surface
staining was analyzed using the FACS Calibur FL1-H
channel.
Bactericidal assay
The assay was performed as previously described [23].
Reaction mixtures contained approximately 400 col-
ony-forming units (CFU), 20% human serum with no
detectable bactericidal activity against the test isolates
as complement source and serial dilutions of the anti-
ACWY capsule antiserum or the anti-LPS mAb in
serial 4-fold dilutions (stock 1 mg/mL). Bactericidal
titers were defined as the dilution of serum or mAb
resulting in 50% decrease of CFU/mL after 60 minutes
incubation at 37°C compared to the CFU/mL in the
control reactions at time 0 [24,25]. Antibody titers were
log10 transformed, and bactericidal titers <10 were
assigned the value 5. Data analysis was carried out
using GraphPad Prism version 7.0b software.
Characterization of capsular polysaccharide
produced by the different serogroup A isolates
Capsular polysaccharide identity and O-acetylation
levels were analyzed by proton high-resolution magic
angle spinning (HR–MAS) nuclear magnetic resonance
(NMR). Data were collected on entire bacteria in het-
erogeneous phase to verify capsular polysaccharide pre-
sence and to determine the O-acetylation level. Bacteria
were grown overnight in 50 mL of MH medium up to
an OD of 4–5. Cultures were treated with p-formalde-
hyde (final concentration 0.1% w/v) to inactivate the
bacteria. Samples were pelleted by centrifugation
(4500 g for 2 min) and washed three times with
10 mM potassium phosphate buffer in deuterated
water. Each compact pellet was transferred into a Kel-
F disposable insert for a 50 µL volume and then spun in
a 4-mm MAS ZrO2 rotor (Bruker, Billerica, MA, USA).
Proton HR–MAS NMR experiments were recorded by
a Bruker Avance III 400-MHz spectrometer, using a
Bruker 4-mm HR–MAS probe. Samples were spun at
4.5 kHz and recorded at 25°C. Proton spectra were
acquired with diffusion filter pulse sequence to remove
sharp lines arising from low-molecular-mass species in
solution. Spectra were collected with 32 k data points
over a 10-ppm spectral width. The transmitter was set
at the HDO frequency, which was also used as refer-
ence signal (4.79 ppm). The TopSpin 2.1 software pack-
age (Bruker) was used for data acquisition and
processing of all spectra was done with
MestReNova 10.0.
The amount of capsular polysaccharide was quanti-
fied by high-performance anion-exchange chromato-
graphy with pulsed amperometric detection (HPAEC-
PAD). Samples were desalted on PD-10 desalting col-
umns (GE Healthcare Life Sciences) and treated by acid
hydrolysis with trifluoroacetic acid at a final concentra-
tion of 2 M in order to release the capsule repeating
units without their degradation. Samples were heated at
100°C for 2 hours, then chilled at 2–8°C for about
30 minutes, 700 μL 2 M NaOH were added and samples
filtered with 0.45 µm Acrodisc® (PALL, Port
Washington, NY, USA) filters before analysis. A pure
preparation of serogroup A polysaccharide obtained
from GSK Manufacturing (Siena, Italy) was used for
building a calibration curve in a range of 0.5–8 µg/mL.
The HPAEC-PAD was performed with a Dionex
ICS3000 equipped with a CarboPac PA1 column
(4 x 250 mm; Dionex, Sunnyvale, CA, USA) coupled
with a PA1 guard column (4 x 50 mm; Dionex).
Samples were run with a flow rate of 1 mL/min, using
a gradient in 10 minutes from 100 mM to 500 mM
sodium acetate in 100 mM NaOH. The effluent was
monitored using an electrochemical detector in the
pulse amperometric mode with a gold working elec-
trode and an Ag/AgCl reference electrode. A quadru-
ple-potential waveform for carbohydrates was applied.
The resulting chromatographic data were processed
using the Chromeleon software 6.8.
Results
Capsular polysaccharide expression in spontaneous
capsule synthesis gene mutants
Our whole genome sequencing analysis of 100 clonally
related Neisseria meningitidis serogroup A ST-7
(n = 50) and ST-2859 (n = 50) case and carriage isolates
revealed that the csaABCD-ctrABCD-ctrEF capsule
polysaccharide synthesis locus represents a spontaneous
point mutation hotspot [12]. Thirteen of the 100 ana-
lyzed isolates carried spontaneous non-synonymous
point mutations or stop codons in the csaABCD-
ctrABCD-ctrEF capsule polysaccharide synthesis locus.
Of these 13 mutants, 11 were carriage isolates and two
(1573 and 2008) invasive case isolates (Table 1). Flow
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cytometric analyzes were firstly performed on five ST-7
and six ST-2859 randomly selected isolates belonging to
the 87 of 100 isolates with no point mutations in the
capsule synthesis locus [12]. These showed only minor
variations in staining intensity with either the anti-A
capsule specific mAb 95/674 or an anti-ACWY capsule
antiserum (Supplementary Figure 1). For further ana-
lysis, three isolates (1446, 2187 and 2602) harbouring
wild type csaABCD-ctrABCD-ctrEF genes were used as
references. Capsule expression of mutants and refer-
ence isolates were analyzed both by HPAEC-PAD
(Table 1) and by flow cytometry with anti-serogroup
A capsule antibodies (Figure 1). The reference isolates
expressed between 34.9 and 58.1 µg/mL/OD capsule
(Table 1) and there was a good correlation between
the measured amounts of O-acetylated capsule polysac-
charide and the fluorescence intensity (shown for
selected isolates in Figure 1).
The mutant isolate 1976 harbouring a non-synon-
ymous SNP in the ctrE gene, which encodes a protein
required for translocation and surface expression of the
lipidated capsular polysaccharide [26], showed no
Figure 1. Flow cytometric analysis of the binding of the anti-A capsule specific mAb 95/674 (A) and of mouse anti-ACWY capsule
antiserum to meningococcal cells (B). The fluorescence intensity of fixed bacterial cells was determined (counts). Isolate 2602:
reference isolate; isolate 1976: no capsule expression in the mutant carrying a non-synonymous SNP in the ctrE gene responsible for
translocation of the polysaccharide; isolate 2008: increased capsule expression in the mutant carrying a non-synonymous SNP in the
csaB gene that codes for a capsule polymerase; isolate 1666: lack of binding of antibodies to the mutant carrying a stop mutation in
the csaC gene that encodes an O-acetyltransferase.
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staining with the capsule-specific monoclonal or poly-
clonal antibodies (Figure 1). It was also negative in the
HPAEC-PAD analysis (Table 1), confirming lack of
polysaccharide expression. Equally negative in both
assays (Table 1) was isolate 2389 with a stop codon in
the csaD gene encoding a protein predicted to be
involved in either capsule transport or in cross-linking
of the capsule to the meningococcal cell surface [16]. In
contrast, isolate 1573 harbouring a non-synonymous
mutation in the ctrD gene, encoding an ATP binding
protein involved in capsule transport [16], showed no
phenotypic changes and a normal amount of capsule
(42.2 µg/mL/OD; Table 1). Isolate 1573 is one of the
two case isolates included in the analysis.
In isolates 2717 and 2617 harboring non-synon-
ymous point mutations in the csaA gene, which
encodes an UDP-N-acetyl-D-glucosamine-2-epimerase
converting UDP-GlcNAc into UDP-N-acetyl-D-man-
nosamine [27], the amount of capsule was reduced to
8.5 and 22.7 µg/mL/OD, respectively (Table 1).
A range of different effects were observed for muta-
tions in the csaB gene, encoding a capsule polymerase
linking ManNAc-phosphate monomers together [27].
No capsule production was found in isolate 1921 with a
stop codon in the csaB gene and in isolate 2206, one of
the six mutants with a non-synonymous csaB point
mutation causing a G386D amino acid exchange
(Figure 2; Table 1). Reduced capsule expression
(<10 µg/mL/OD) was found in two of the other five
csaB mutants (isolates 2856 and 2857; Table 1) carrying
the same mutation causing a P143S amino acid
exchange (Table 1). In contrast, an increased capsule
expression of 61.4 and 71.2 µg/mL/OD was found in
two other non-synonymous csaB mutant isolates 2008
and 2025, respectively (shown for the case isolate 2008
in Figure 1). These two isolates were also carrying
identical mutations causing an I82V amino acid
exchange (Table 1). Only one csaB mutant (1471)
with an amino acid exchange (S59Y) closer to the
N-terminus did not show a change in polysaccharide
expression level compared to the reference isolates
(Table 1).
Moreover, the O-acetylation levels of the cell asso-
ciated polysaccharide were determined by HR-MAS
NMR (Table 1, Figure 2). The monitoring of the
anomeric proton at carbon 1 of the ManNAc-
Figure 2. HR MAS-NMR spectra (from 5.2 to 5.8 ppm characteristic for H1 signals of O-acetylated (OAc) and not O-acetylated (deOAC)
sugar units indicated in the structure of the serogroup A polysaccharide repeating unit of three selected isolates compared to the
reference isolate 2602. No capsule expression in isolate 1976 carrying a non-synonymous SNP in the ctrE gene responsible for
translocation of the polysaccharide; similar O-acetylation level with respect to the reference in isolate 2008 carrying a non-
synonymous SNP in the csaB gene that codes for a capsule polymerase; no O-acetylation in isolate 1666 carrying a stop mutation
in the csaC gene that encodes an O-acetyltransferase.
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phosphate residue constituting the repeating unit of the
serogroup A capsular polysaccharide provided a tool
for evaluating levels of O-acetylation [28]. Two separate
peaks, one of the O-acetylated form at lower-field sig-
nal (5.40 ppm) and the other of the non-O-acetylated
form at upper-field signal (5.35 ppm) were resolved
(Figure 2). Isolate 1666, with a stop codon in the csaC
gene encoding an O-acetyltransferase with specificity
for the O-3 and O-4 positions in ManNAc [17],
expressed normal amounts of capsular material
(Table 1), but no O-acetylation was detected
(Figure 2). Neither the monoclonal nor the polyclonal
capsular polysaccharide antiserum was able to bind to
this non-O-acetylated polysaccharide (Figure 1). All
other isolates analyzed showed O-acetylation levels
between 40 and 60% (Table 1).
Sensitivity of capsule mutants to antibody
mediated bactericidal activity
The monoclonal anti-A capsule specific mAb 95/674
showed no bactericidal activity, therefore, bactericidal
assays were performed with the mouse anti-ACWY cap-
sule antiserum and with the anti-LPS mAb EI9.2. Both
were bactericidal for the wild-type control isolates. Due to
lack of the target antigen, the polyclonal anti-ACWY
capsule antiserum elicited no bactericidal effect against
the four mutants deficient in capsule production (isolates
1976, 2206, 2389, 1921) (shown for isolate 1976 in
Figure 3) and the csaAmutant 2717 with strongly reduced
capsule production (Table 1). Likewise, no bactericidal
activity was observed with the anti-ACWY capsule anti-
serum against the O-acetylation deficient csaC mutant
isolate (1666; Figure 3). In the case of the two isolates
with non-synonymous mutations in the csaB gene (2025
and 2008) that increased the expression of capsular poly-
saccharide (Table 1), the bactericidal activity elicited by
the polyclonal anti-ACWY capsule antiserum was
strongly reduced (shown for isolate 2008 in Figure 3). In
contrast to all other isolates, these two over-expressing
mutants additionally showed increased resistance to the
bactericidal activity mediated by the anti-LPS mAb
(Figure 3).
The anti-capsular antibodies were not able to cause
C3b and C4b deposition on the surface of isolates lack-
ing capsule (1976, 2389, 1921 and 2206) or having a
strongly reduced capsule expression (2717), as shown
for isolate 1976 in Figure 4. This correlates well with
the observed lack of complement-mediated killing
(Figure 3). Likewise, there was no C3b and C4b deposi-
tion (Figure 4), no bactericidal activity (Figure 3) and no
binding of the anti-ACWY capsule antiserum (Figure 1)
with the isolate 1666 deficient in O-acetylation. In con-
trast, the anti-LPS mAb caused C3b and C4b deposition
Figure 3. Effect of point mutations in the capsule synthesis locus on bactericidal activity mediated by anti-ACWY capsule antiserum
and anti-LPS mAb. Typical results are shown for selected reference and mutant isolates. Reference isolate 2602: sensitive against
both anti-ACWY capsule antiserum and anti-LPS mAb; isolate 1976 lacking capsule due to a non-synonymous SNP in the ctrE gene:
lack of activity of anti-ACWY capsule antiserum; isolate 2008 expressing more polysaccharide than the reference isolate as a result of
a non-synonymous mutation in the csaB gene: generally reduced bactericidal effect irrespective of the specificity of the antibodies;
isolate 1666 expressing non-O-acetylated capsular polysaccharide: lack of activity of anti-ACWY capsule antiserum. Error bars
represent standard error of the mean titer of triplicate measurements in three independent experiments. The bottom dotted line
indicates the lowest serum dilution (1:10) and highest mAb concentration (100 µg/mL) tested.
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in these isolates (Figure 4). In the case of the two csaB
capsule over-expressing mutants 2025 and 2008, C3b
and C4b deposition caused by the anti-LPS mAb was
strongly reduced (shown for the case isolate 2008 in
Figure 4). Anti-ACWY capsule antiserum bound
strongly to these two isolates (Figure 1), and C3b and
C4b deposition was only slightly affected (Figure 4),
while the sensitivity to the bactericidal activity was
strongly reduced (Figure 3).
Discussion
Our results show that natural populations of N. meningi-
tidis are remarkably diverse during rapid spread of clones
in the course of epidemics. The capsule synthesis locus
has been found to be a hot spot of point mutations [12],
and here we have analyzed the phenotype of 13 isolates
with non-synonymous SNPs or stop codons in the cap-
sule synthesis locus identified among 100 closely related
A:ST-7 and A:ST-2859 isolates. Lack of O-acetylation in
one csaC mutant and lack of capsule expression in four
csaB, csaD and ctrE mutants abrogated binding and bac-
tericidal activity of capsule specific antibodies. In two
isolates with non-synonymous point mutations in the
csaB gene encoding the capsule polymerase, the capsule
expression was increased while the bactericidal activity of
both capsule- and LPS-specific antibodies was strongly
reduced. Absence of mutants with synonymous point
Figure 4. Flow cytometric analysis of the deposition of human C3b and C4b on fixed bacterial cells. Anti-ACWY capsule antiserum
(diluted 1:50) or anti-LPS mAb EI9.2 (4 µg/mL) was used together with 5% IgG depleted human serum to investigate the effect of the
mutations on antibody mediated C3b and C4b deposition. Typical results are shown for one of the reference isolates and for selected
mutant isolates. The fluorescence intensity of fixed bacterial cells was determined (counts). Grey filled area: cells only incubated with
secondary antibody; black thin line: negative control with 4 µg/mL of an unrelated IgG1 mAb; grey thick line: anti-ACWY capsule
antiserum; black thick line: anti-LPS mAb. Reference isolate 2602: C3 and C4 deposition is caused both by anti-capsule and anti-LPS
antibodies; isolate 1976 lacking capsule due to a non-synonymous SNP in the ctrE gene: no C3 and C4 deposition with anti-capsule
antibodies; isolate 2008 expressing more polysaccharide than the reference isolates as a result of a non-synonymous mutation in the
csaB gene: C3 and C4 deposition by anti-LPS mAb is strongly reduced; isolate 1666 expressing non-O-acetylated capsular
polysaccharide: no C3 and C4 deposition caused by polyclonal anti-ACWY capsule antiserum.
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mutation in the capsule locus in the analyzed bacterial
populations [12] is speaking for (immune)selection of
these capsule mutants.
While there is no doubt that the lack of capsule
production in isolate 1921 is related to the stop codon
in the csaB gene encoding the capsule polymerase, we
have no formal proof that the non-synonymous muta-
tions in csaB did directly result in lack of capsule
expression in isolate 2206, reduced expression in iso-
lates 2856 and 2857 or increased expression in strains
2025 and 2008. Strikingly however, the two over-pro-
ducer isolates shared the same amino acid exchange
(I82V) and also the two isolates with reduced capsule
production shared the same (P143S) exchange. Future
analysis of the structure of the polymerase and analyzes
with recombinantly expressed mutant versions of the
enzyme carrying the observed amino acid exchanges
could provide molecular insight into structure-activity
relation of the polymerase.
Polysaccharide capsules are thought to protect
meningococci from phagocytic killing, opsonisation
and complement-mediated bactericidal activity [29].
They are therefore regarded as a key virulence factor
of invasive strains and represent the target of the cur-
rently available vaccines against serogroup A, C, Y and
W meningococcal invasive disease [30]. After the intro-
duction of the meningococcal serogroup A polysac-
charide vaccine MenAfriVac [31–33], W, C, X and Y
clones represent the main etiological agent of epidemics
in the meningitis belt [34]. Therefore, it is important to
understand the dynamics of the capsule synthesis genes
and how mutations in this locus translate into pheno-
typic, structural and functional effects. Changes in cap-
sule expression may in particular affect the bactericidal
activity of capsule specific antibodies, which represent a
correlate of protection for the capsule polysaccharide
based vaccines.
In industrialized countries, the carried meningococ-
cal populations are complex, temporarily relatively
stable in composition and are comprising up to 50%
serologically nongroupable isolates [35]. These include
lineages harboring the capsule null locus lacking the
genes required for capsule synthesis and transport [36],
which are rarely associated with invasive disease [37].
In the African meningitis belt, lack of a diverse and
temporally stable resident meningococcal pharyngeal
flora is a characteristic feature of meningococcal colo-
nization [14]. A small proportion of capsule deficient
mutants related to the temporally dominating capsule-
expressing isolates are commonly found [15,38]. They
may be able to persist longer in the nasopharynx when
a carrier has developed a capsule specific secretory
antibody response. Furthermore, absence of capsule
has been shown to generally facilitate the intimate
attachment of meningococci to the human nasophar-
yngeal epithelium [30,39] via adhesins such as Opa and
Opc [40], which are more efficiently shielded by the
capsule than pili [41]. Among the 11 carriage mutants
with point mutations in the capsule locus analyzed
here, we found four isolates (1976, 2389, 1921, and
2206) with mutations in either the ctrE, csaB or csaD
genes that lead to lack of capsule polysaccharide expres-
sion. Another four carriage isolates (2856, 2857, 2717,
and 2617) with mutations in csaA or csaB genes pro-
duced reduced amounts of capsule. Thus, the serogroup
A carriage population comprised a high proportion
(8%) of mutants with complete or partial loss of capsule
production, which may allow them to adhere more
efficiently to the nasopharyngeal epithelium [30,39].
One of the two case isolates with mutations in cap-
sule synthesis genes (2008), and also one carriage
mutant (2025) showed an approximately 1.5-fold
increase in capsule production compared to the refer-
ence isolates. These two capsule overproducing isolates
with identical non-synonymous mutations in the csaB
gene encoding a capsule polymerase linking ManNAc-
phosphate monomers showed enhanced resistance to
the bactericidal activity of both anti-LPS and anti-cap-
sular antibodies. The increased amount of polysacchar-
ide may reduce the bactericidal activity of the terminal
complex of complement by enhanced shielding of the
cell membranes [29] and interfere with antibody recog-
nition of deeper cell surface structures, such as LPS.
Increased amounts of capsule have also been shown to
physically interfere with the engagement of C1q with
the Fc portions of bound antibodies [42]. Similarly,
hyperencapsulated C:ST-11 isolates from Spain have
been found to be resistant to the bactericidal activity
of vaccine induced anti-capsule antibodies [43]. In
these strains insertion of an IS element has been asso-
ciated with the transcriptional upregulation of both the
css and the ctr operons.
The serogroup A capsular polysaccharide is a homo-
polymer of N-acetyl-mannosamine-phosphate-linked
α1-6. O-acetylation is an important final step modifica-
tion of the A polysaccharide polymer, and a dramatic
reduction in immunogenicity is associated with the
removal of the O-acetyl groups [19,44]. Many patho-
genic bacteria are O-acetylated, but CsaC has no
homology to other known O-acetyltransferases or to
the sialic acid serogroup C, Y, and W capsule
O-acetyltransferases (OatC and OatWY) [17]. In our
study, we found that the carriage isolate 1666 had a
stop mutation in the csaC gene coding for the menin-
gococcal serogroup A O-3 and O-4 ManNAc acetyl-
transferase [17]. Neither the anti-A capsule mAb nor
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the polyclonal anti-capsular antiserum elicited by the
ACWY conjugate vaccine Menveo recognized the non-
O-acetylated polysaccharide resulting in a complete
lack of bactericidal activity of the anti-ACWY capsule
antiserum. In line with this, it has been observed [44]
that the majority of the antibodies elicited by vaccina-
tion with a conjugate serogroup A polysaccharide vac-
cine were specific for epitopes involving O-acetyl
groups. In contrast, the O-acetyl groups on the menin-
gococcal serogroup C polysaccharide are not necessary
for induction of protective antibodies [45]. Our results,
therefore, underline the importance of O-acetylation
for the immunogenicity of the N. meningitidis ser-
ogroup A polysaccharide. Loss of O-acetylation may
thus represent an immune evasion mechanism.
Taken together, our results demonstrate that varia-
tion in the amount and structure of the expressed
capsular polysaccharide due to point mutations is com-
mon in hypervirulent serogroup A meningococcal
populations. In general, the genomic diversity of epi-
demic N. meningitidis lineages is extensive and is pri-
marily attributed to the natural competence of the
meningococci for transformation and homologous
recombination rather than point mutation [12]. A
reversion of the capsule mutants to encapsulated and
O-acetylated phenotypes may therefore potentially
occur rather by horizontal gene transfer than by reverse
mutation. Reduction or loss of capsule polysaccharide
production may bring advantages with respect to colo-
nization efficacy, while capsule overproduction or lack
of O-acetylation may increase resistance against host
immune defense mechanisms during invasion of the
bloodstream. Further studies are required to determine
the impact of diversity in capsule expression on trans-
mission dynamics and colonization patterns. Variation
of capsule expression is of importance both for vaccine
induced anti-capsular immunity and for meningococcal
diagnostics, speaking for a combination of serogroup-
ing and genotyping diagnostic approaches.
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